Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 9:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 108 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Divalproex Sodium (Depakote) Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study to Evaluate the Effect of Inhibition of UGTs on the PK of Ecopipam and Its Active Metabolite

NCT04902105
View directory record Official record
Conditions
Drug Interaction
Interventions
ecopipam HCL, Mefenamic acid, Divalproex Sodium ER
Drug
Lead sponsor
Emalex Biosciences Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 4, 2026, 9:18 AM EDT
Completed Phase 3 Interventional Results available

Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression

NCT01284517
View directory record Official record
Conditions
Bipolar Depression
Interventions
Lurasidone, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
22
States / cities
Costa Mesa, California • Riverside, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2013 · Synced Oct 4, 2026, 9:18 AM EDT
Completed Phase 2 Interventional

Drug Treatment for Alcoholics With Bipolar Disorder

NCT00000439
View directory record Official record
Conditions
Alcoholism, Bipolar Disorder
Interventions
sodium valproate
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 4, 2026, 9:18 AM EDT
Completed Phase 3 Interventional

Divalproex Sodium (Depakote) for Explosive Tempers in Adolescents and Adults

NCT00218114
View directory record Official record
Conditions
Attention Deficit and Disruptive Behavior Disorders, Marijuana Abuse
Interventions
Divalproex Sodium, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
12 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 4, 2026, 9:18 AM EDT
Completed Phase 2 Interventional

Pediatric Switch Study for Children and Adolescent Patients With Epilepsy

NCT00646711
View directory record Official record
Conditions
Pediatric Epilepsy
Interventions
Depakote Delayed-Release/Depakote Sprinkle, Depakote ER
Drug
Lead sponsor
Abbott
Industry
Eligibility
6 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 28, 2008 · Synced Oct 4, 2026, 9:18 AM EDT
Completed Phase 4 Interventional Results available

Treatment of Bipolar Mania in Older Adults

NCT00254488
View directory record Official record
Conditions
Bipolar Disorder, Mania
Interventions
Lithium (LI), Divalproex (DV)
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
60 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
7
States / cities
Flowood, Mississippi • White Plains, New York • Durham, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 4, 2026, 9:18 AM EDT
Completed Phase 4 Interventional

Treatment and Outcome of Early Onset Bipolar Disorder

NCT00048802
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium, Olanzapine, Divalproex, Risperidone, Quetiapine, Ziprasidone, Aripriprazole
Drug
Lead sponsor
Northwell Health
Other
Eligibility
10 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2014 · Synced Oct 4, 2026, 9:18 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder

NCT00081380
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Seroquel®, quetiapine fumarate (atypical antipsychotic), lithium (mood stabilizer), divalproex (mood stabilizer)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
81
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 78 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2008 · Synced Oct 4, 2026, 9:18 AM EDT
Completed Phase 3 Interventional Results available

This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296

NCT01575561
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Lurasidone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
25
States / cities
Dothan, Alabama • Glendale, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2016 · Synced Oct 4, 2026, 9:18 AM EDT
Withdrawn Phase 2 Interventional

Treatment of Children With Autism Spectrum Disorders and Epileptiform EEG With Divalproex Sodium

NCT02094651
View directory record Official record
Conditions
Autism
Interventions
divalproex sodium, Placebo
Drug · Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
4 Years to 10 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Louisville, Kentucky • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Oct 4, 2026, 9:18 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Safety and Efficacy of Divalproex and Quetiapine in Elderly Alzheimer's Dementia Patients

NCT00375557
View directory record Official record
Conditions
Alzheimer's Disease, Dementia, Behavioral Symptoms
Interventions
Divalproex ER, Quetiapine
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
55 Years to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Oct 4, 2026, 9:18 AM EDT
Completed Phase 3 Interventional

Effectiveness of Family-Focused Treatment Plus Pharmacotherapy for Bipolar Disorder in Adolescents

NCT00332098
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Family-Focused Treatment Plus Pharmacotherapy, Enhanced Care Plus Pharmacotherapy
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
13 Years to 17 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
3
States / cities
Boulder, Colorado • Cincinnati, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 4, 2026, 9:18 AM EDT
Not yet recruiting Phase 2Phase 3 Interventional

Valproic AcId for Traumatic BRAin INjury Trial

NCT07166393
View directory record Official record
Conditions
Moderate Traumatic Brain Injury (TBI), Severe Traumatic Brain Injury
Interventions
Valproic Acid (VPA), Standard of care treatment + normal saline
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
8
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 4, 2026, 9:18 AM EDT
Terminated Phase 3 Interventional

Depakote Extended Release (ER) Versus Seroquel for Agitated Behaviors in Nursing Home Care Unit Patients With Dementia

NCT00315900
View directory record Official record
Conditions
Agitation, Dementia
Interventions
Depakote ER, Seroquel
Drug
Lead sponsor
Tuscaloosa Research & Education Advancement Corporation
Other
Eligibility
55 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Tuscaloosa, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Oct 4, 2026, 9:18 AM EDT
Completed Phase 4 Interventional Results available

Effect of Valproic Acid Concentration on Photic Response

NCT00609245
View directory record Official record
Conditions
Photosensitive Epilepsy
Interventions
Valproic Acid, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
15 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Chesterfield, Missouri • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 4, 2026, 9:18 AM EDT
Completed Phase 2 Interventional

Depakote ER Plus an Atypical Antipsychotic Vs. an Atypical Antipsychotic Alone in the Treatment of Schizophrenia

NCT00073164
View directory record Official record
Conditions
Schizophrenia
Interventions
Divalproex Sodium Extended-Release Tablets, Olanzapine, Risperidone
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
35
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Anaheim, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2006 · Synced Oct 4, 2026, 9:18 AM EDT
Completed Phase 3 Interventional Results available

Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on)

NCT00868452
View directory record Official record
Conditions
Bipolar Depression
Interventions
lurasidone + (lithium or divalproex), Placebo + (lithium or divalproex)
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
27
States / cities
Little Rock, Arkansas • Anaheim, California • Chino, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2014 · Synced Oct 4, 2026, 9:18 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Double-blind, Placebo-Controlled Divalproex Sodium ER in Bipolar I or Bipolar II Depression

NCT00194116
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Divalproex Sodium ER, Placebo
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
16 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Oct 4, 2026, 9:18 AM EDT
Completed Phase 1 Interventional

A Drug Interaction Study of Valproic Acid and Paliperidone Extended-Release (ER) in Patients With Schizophrenia, Bipolar I Disorder, or Schizoaffective Disorder

NCT01094249
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Psychotic Disorders
Interventions
divalproex sodium ER/paliperidone ER
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
3
States / cities
Kissimmee, Florida • Austin, Texas • Portsmount, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Oct 4, 2026, 9:18 AM EDT
Withdrawn Phase 2 Interventional

A Study of Divalproex Sodium in Children With ASD and Epileptiform EEG

NCT01170325
View directory record Official record
Conditions
Autism, Autism Spectrum Disorders
Interventions
Divalproex Sodium, Placebo Comparator
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
3 Years to 10 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 4, 2026, 9:18 AM EDT
Not listed Phase 1 Interventional

A Study in Stable Epilepsy Patients Comparing Brand and Generic Divalproex Sodium Extended Release Tablets

NCT01898676
View directory record Official record
Conditions
Epilepsy
Interventions
Divalproex Sodium Extended-release 250mg, DEPAKOTE 250mg
Drug
Lead sponsor
Vince & Associates Clinical Research, Inc.
Other
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2013 · Synced Oct 4, 2026, 9:18 AM EDT
Completed Phase 1 Interventional Results available

Characterization of Epilepsy Patients BEEP 2b

NCT02707965
View directory record Official record
Conditions
Epilepsy
Interventions
Oxcarbazepine (brand name vs generic drugs), Divalproex Sodium (brand name vs generic drugs), Carbamazepine (brand name vs generic drugs), Lamotrigine (brand name vs generic drugs), levetiracetam (brand name vs generic drugs), Topiramate (brand name vs generic drugs), Zonisamide (brand name vs generic drugs), Phenytoin sodium (brand name vs generic drugs)
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 76 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 27, 2020 · Synced Oct 4, 2026, 9:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Divalproex Sodium Delayed-Release Tablets, 500 mg

NCT01184391
View directory record Official record
Conditions
Healthy
Interventions
DEPAKOTE® Tablets, 500 MG, DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 18, 2010 · Synced Oct 4, 2026, 9:18 AM EDT
Withdrawn Phase 2 Interventional

Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients

NCT04531592
View directory record Official record
Conditions
Acute Kidney Injury, Ischemia Reperfusion Injury
Interventions
Valproic acid, Isotonic saline solution
Drug
Lead sponsor
Westat
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
San Francisco, California • Denver, Colorado • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 4, 2026, 9:18 AM EDT